Classification by type of ventricular arrhythmia predicts frequency of adverse cardiac events from flecainide

Antiarrhythmic therapy is known to be associated with a significant risk of adverse cardiac reactions, including a proarrhythmic response. This study assessed in 1,330 patients followed up for 292 +/- 393 days the predictive value for cardiovascular safety of a system by which patients were classified according to ventricular arrhythmias on entry, presence or absence of organic heart disease and drug dose for flecainide acetate. Baseline arrhythmia subgroups included patients with premature ventricular complexes only, nonsustained ventricular tachycardia, and sustained ventricular tachycardia. Proarrhythmic events occurred in 6.8% of patients overall and were serious in 2.3% and lethal in 1.0%. However, proarrhythmia was highly dependent on arrhythmia class on entry: serious nonlethal proarrhythmic events occurred in 6.6% of patients with sustained ventricular tachycardia, only 0.9% with nonsustained ventricular tachycardia and 0% with premature ventricular complexes (p less than 0.01). Proarrhythmic death occurred in 3.1% of patients with sustained ventricular tachycardia, 0.2% with nonsustained ventricular tachycardia and 0% with premature ventricular complexes only (p less than 0.01). Proarrhythmia was also influenced by the presence of structural heart disease: serious nonlethal proarrhythmia occurred in 2.6% of patients with versus 0.4% of those without organic heart disease, and death occurred in 1.2 versus 0%, respectively. These adverse events were also dependent on dosing regimen. Flecainide caused premature discontinuation due to new or worsened heart failure in 1.4% of patients, all with underlying organic heart disease; however, heart failure was not clearly related to dose or type of arrhythmia. Symptomatic conduction disturbances occurred in 2.2%, and were predicted by preexistent sinus node disease but not by other baseline features.(ABSTRACT TRUNCATED AT 250 WORDS)

This article has been cited by other articles:

				S. Singla, P. Karam, A. J. Deshmukh, J. Mehta, and H. Paydak Review of Contemporary Antiarrhythmic Drug Therapy for Maintenance of Sinus Rhythm in Atrial Fibrillation Journal of Cardiovascular Pharmacology and Therapeutics, March 1, 2012; 17(1): 12 - 20. [Abstract] [PDF]

				B. D. Guth Preclinical Cardiovascular Risk Assessment in Modern Drug Development Toxicol. Sci., May 1, 2007; 97(1): 4 - 20. [Full Text] [PDF]

				S. Ranger and S. Nattel Determinants and Mechanisms of Flecainide-Induced Promotion of Ventricular Tachycardia in Anesthetized Dogs Circulation, September 1, 1995; 92(5): 1300 - 1311. [Abstract] [Full Text]

				M. Restivo, H. Yin, E. B. Caref, A. I. Patel, G. Ndrepepa, M. J. Avitable, M. A. Assadi, N. Isber, and N. El-Sherif Reentrant Arrhythmias in the Subacute Infarction Period : The Proarrhythmic Effect of Flecainide Acetate on Functional Reentrant Circuits Circulation, February 15, 1995; 91(4): 1236 - 1246. [Abstract] [Full Text]

				R. H. Falk Proarrhythmia in Patients Treated for Atrial Fibrillation or Flutter Ann Intern Med, July 15, 1992; 117(2): 141 - 150. [Abstract] [PDF]

				A. C. Powell, M. R. Gold, R. Brooks, H. Garan, J. N. Ruskin, and B. A. McGovern Electrophysiologic Response to Moricizine in Patients with Sustained Ventricular Arrhythmias Ann Intern Med, March 1, 1992; 116(5): 382 - 387. [Abstract] [PDF]

				J. H. Gurwitz and J. Avorn The Ambiguous Relation between Aging and Adverse Drug Reactions Ann Intern Med, June 1, 1991; 114(11): 956 - 966. [Abstract] [PDF]

				M. E. Josephson Antiarrhythmic Agents and the Danger of Proarrhythmic Events Ann Intern Med, July 15, 1989; 111(2): 101 - 103. [Abstract] [PDF]

				R. H. Falk Flecainide-Induced Ventricular Tachycardia and Fibrillation in Patients Treated for Atrial Fibrillation Ann Intern Med, July 15, 1989; 111(2): 107 - 111. [Abstract] [PDF]

				H. G. McCoy and K. R. Labrosse State of the Art: Measurement of Drug Concentrations for Therapeutic Drug Monitoring Journal of Pharmacy Practice, January 1, 1989; 2(6): 335 - 346. [PDF]